Remove Healthcare Remove Manufacturing Remove Pharma Remove Prescription
article thumbnail

America’s healthcare costs are in deep crisis

World of DTC Marketing

SUMMARY: The media loves to blame pharma companies for high healthcare costs, but unless we start to invest in healthy lifestyles, we’re headed for a healthcare crisis the likes of which we have never experienced. Forget the fact that prescription drugs only account for $.10 This means higher healthcare costs.

article thumbnail

AbbVie continues to be what’s wrong with big pharma

World of DTC Marketing

I continue to believe that there are very good people who care about patients working within pharma but it’s hard to understand how anyone who works for AbbVie can feel good about their employer. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S.

Pharma 202
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why is the healthcare industry hesitant to join the metaverse?

Pharmaceutical Technology

The Covid-19 pandemic pushed the healthcare industry toward rapid digitalisation, with the rise of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology now changing the way healthcare is delivered and improving patient outcomes.

article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.

article thumbnail

GAMP 5 update: computerized system expectations for pharma manufacturers

European Pharmaceutical Review

As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.”

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

article thumbnail

Pharma Has a Pull-Through Problem—The Answer is Data

PM360

Most market access teams at pharmaceutical and biotech manufacturers have the same problem: evidence of clinical effectiveness isn’t always enough to affect prescribing behavior, often due to—accurate or misperceived—access and affordability concerns. For pharma, it can sometimes feel like a situation beyond their control.

Pharma 98